Dyadic International (DYAI) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Dyadic International (DYAI) over the past year, losing 54.3% versus a loss of 60.7%. Over five years, DYAI leads with a -90.8% price change compared with -98.1% for PASG. Dyadic International is the larger company by market cap ($17.8 million vs $12.2 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | PASG |
|---|---|---|
| Share price | $0.4444 | $3.78 |
| Market cap | $17.80M | $12.16M |
| 1-day change | -2.65% | -1.95% |
| YTD return | -52.72% | -67.97% |
| 1-year return | -60.67% | -54.35% |
| 5-year return | -90.84% | -98.06% |
| EPS (TTM) | $-0.23 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $20.00 |
| 52-week low | $0.34 | $3.29 |
| Distance from 52-week high | -72.23% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1137.62% | +310.05% |
| Average volume | 201.91K | 26.11K |
| Shares outstanding | 40.06M | 3.22M |
| Employees | 5 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Healthcare · Biotechnology · 5 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
DYAI vs PASG FAQ
Which is bigger, Dyadic International or Passage Bio?
Dyadic International (DYAI) is larger, with a market capitalization of $17.80M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, DYAI or PASG?
PASG returned -54.35% over the past 12 months, compared with -60.67% for DYAI (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.